BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

739 related articles for article (PubMed ID: 29553571)

  • 1. Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia.
    Cloos J; Harris JR; Janssen JJWM; Kelder A; Huang F; Sijm G; Vonk M; Snel AN; Scheick JR; Scholten WJ; Carbaat-Ham J; Veldhuizen D; Hanekamp D; Oussoren-Brockhoff YJM; Kaspers GJL; Schuurhuis GJ; Sasser AK; Ossenkoppele G
    J Vis Exp; 2018 Mar; (133):. PubMed ID: 29553571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunophenotypic Detection of Measurable Residual (Stem Cell) Disease Using LAIP Approach in Acute Myeloid Leukemia.
    Zeijlemaker W; Kelder A; Cloos J; Schuurhuis GJ
    Curr Protoc Cytom; 2019 Dec; 91(1):e66. PubMed ID: 31763792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic impact of minimal residual disease analysis by flow cytometry in patients with acute myeloid leukemia before and after allogeneic hemopoietic stem cell transplantation.
    Bastos-Oreiro M; Perez-Corral A; Martínez-Laperche C; Bento L; Pascual C; Kwon M; Balsalobre P; Muñoz C; Buces E; Serrano D; Gayoso J; Buño I; Anguita J; Diéz-Martín JL
    Eur J Haematol; 2014 Sep; 93(3):239-46. PubMed ID: 24702162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leukemia-associated immunophenotypes subdivided in "categories of specificity" improve the sensitivity of minimal residual disease in predicting relapse in acute myeloid leukemia.
    Rossi G; Giambra V; Minervini MM; De Waure C; Mancinelli S; Ciavarella M; Sinisi NP; Scalzulli PR; Carella AM; Cascavilla N
    Cytometry B Clin Cytom; 2020 May; 98(3):216-225. PubMed ID: 31697027
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prognosticating relapse risk based on multiparameter flow cytometric assessment of minimal residual disease in patients with acute myeloid leukemia].
    Wan SG; Zhao H; Sun XJ; He JJ; Su L; Xu J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):557-62. PubMed ID: 19549363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients.
    San Miguel JF; Martínez A; Macedo A; Vidriales MB; López-Berges C; González M; Caballero D; García-Marcos MA; Ramos F; Fernández-Calvo J; Calmuntia MJ; Diaz-Mediavilla J; Orfao A
    Blood; 1997 Sep; 90(6):2465-70. PubMed ID: 9310499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study.
    Terwijn M; van Putten WL; Kelder A; van der Velden VH; Brooimans RA; Pabst T; Maertens J; Boeckx N; de Greef GE; Valk PJ; Preijers FW; Huijgens PC; Dräger AM; Schanz U; Jongen-Lavrecic M; Biemond BJ; Passweg JR; van Gelder M; Wijermans P; Graux C; Bargetzi M; Legdeur MC; Kuball J; de Weerdt O; Chalandon Y; Hess U; Verdonck LF; Gratama JW; Oussoren YJ; Scholten WJ; Slomp J; Snel AN; Vekemans MC; Löwenberg B; Ossenkoppele GJ; Schuurhuis GJ
    J Clin Oncol; 2013 Nov; 31(31):3889-97. PubMed ID: 24062400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myeloblasts in normal bone marrows expressing leukaemia-associated immunophenotypes.
    Camburn AE; Petrasich M; Ruskova A; Chan G
    Pathology; 2019 Aug; 51(5):502-506. PubMed ID: 31262563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Detection of Minimal Residual Disease in Acute Myeloid Leukemia by Multi-color Flow Cytometry].
    He C; Zhang QT; Tang P; Sun H
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Apr; 30(2):341-345. PubMed ID: 35395960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Quantification of minimal residual disease by multiparameter flow cytometry in acute myeloid leukemia. From diagnosis to prognosis].
    Kern W; Haferlach T
    Med Klin (Munich); 2005 Jan; 100(1):54-9. PubMed ID: 15654545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Minimal residual disease in acute myeloid leukemia: coming of age.
    Paietta E
    Hematology Am Soc Hematol Educ Program; 2012; 2012():35-42. PubMed ID: 23233558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prognostic significance of minimal residual disease detected by multiparameter flow cytometry in acute myeloid leukemia].
    Wang YZ; Liu YR; Zhu HH; Wu HH; Cao H; Chan Y; Hao L; Jiang B; Huang XJ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Jun; 17(3):551-6. PubMed ID: 19549362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic relevance of treatment response measured by flow cytometric residual disease detection in older patients with acute myeloid leukemia.
    Freeman SD; Virgo P; Couzens S; Grimwade D; Russell N; Hills RK; Burnett AK
    J Clin Oncol; 2013 Nov; 31(32):4123-31. PubMed ID: 24062403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peripheral blood minimal residual disease may replace bone marrow minimal residual disease as an immunophenotypic biomarker for impending relapse in acute myeloid leukemia.
    Zeijlemaker W; Kelder A; Oussoren-Brockhoff YJ; Scholten WJ; Snel AN; Veldhuizen D; Cloos J; Ossenkoppele GJ; Schuurhuis GJ
    Leukemia; 2016 Mar; 30(3):708-15. PubMed ID: 26373238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identifying leukemia-associated immunophenotype-based individualized minimal residual disease in acute myeloid leukemia and its prognostic significance.
    Sui JN; Chen QS; Zhang YX; Sheng Y; Wu J; Li JM; Weng XQ; Chen B
    Am J Hematol; 2019 May; 94(5):528-538. PubMed ID: 30734356
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CD34+CD38-CD123+ Cells Are Present in Virtually All Acute Myeloid Leukaemia Blasts: A Promising Single Unique Phenotype for Minimal Residual Disease Detection.
    Al-Mawali A; Pinto AD; Al-Zadjali S
    Acta Haematol; 2017; 138(3):175-181. PubMed ID: 29065396
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pattern associated leukemia immunophenotypes and measurable disease detection in acute myeloid leukemia or myelodysplastic syndrome with mutated NPM1.
    Zhou Y; Moon A; Hoyle E; Fromm JR; Chen X; Soma L; Salipante SJ; Wood BL; Wu D
    Cytometry B Clin Cytom; 2019 Jan; 96(1):67-72. PubMed ID: 30417521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Introducing minimal residual disease in acute myeloid leukemia.
    Ofran Y; Rowe JM
    Curr Opin Hematol; 2015 Mar; 22(2):139-45. PubMed ID: 25575038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia.
    Inaba H; Coustan-Smith E; Cao X; Pounds SB; Shurtleff SA; Wang KY; Raimondi SC; Onciu M; Jacobsen J; Ribeiro RC; Dahl GV; Bowman WP; Taub JW; Degar B; Leung W; Downing JR; Pui CH; Rubnitz JE; Campana D
    J Clin Oncol; 2012 Oct; 30(29):3625-32. PubMed ID: 22965955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence, sensitivity, and specificity of leukemia-associated phenotypes in acute myeloid leukemia using specific five-color multiparameter flow cytometry.
    Al-Mawali A; Gillis D; Hissaria P; Lewis I
    Am J Clin Pathol; 2008 Jun; 129(6):934-45. PubMed ID: 18480011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.